<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03176472</url>
  </required_header>
  <id_info>
    <org_study_id>REGY-DN-201</org_study_id>
    <nct_id>NCT03176472</nct_id>
  </id_info>
  <brief_title>Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regenacy Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regenacy Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, 2-arm, parallel group study of up to 274 evaluable&#xD;
      patients designed to evaluate the safety and efficacy of the histone deacetylase 6 (HDAC6)&#xD;
      inhibitor ricolinostat for painful DPN.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes an approximately 12 week randomized, double-blind, placebo controlled&#xD;
      Treatment period in which patients will receive either ricolinostat or placebo, followed by&#xD;
      an approximately 12 week open label Safety Extension period during which all patients will&#xD;
      receive ricolinostat 120 mg daily.&#xD;
&#xD;
      Prior to randomization, patients will be enrolled in a baseline Pain Observation period from&#xD;
      Day -14 to Day -1, during which the NRS (average and worst pain) will be recorded daily using&#xD;
      an electronic daily diary that will be completed by patients to allow patients to familiarize&#xD;
      themselves with the pain rating procedures, and to establish a baseline and confirm&#xD;
      eligibility to participate. Patients will also initiate daily dosing during this time to&#xD;
      evaluate compliance eligibility for participation. A daily diary will be used by the patient&#xD;
      to record the pain assessments and rescue medication use. A follow-up phone contact will be&#xD;
      conducted at Day -7 to Day -5 to review diary and dosing compliance.&#xD;
&#xD;
      Following the baseline Pain Observation period, patients who meet entry criteria will be&#xD;
      randomized in a 1:1 ratio to receive either ricolinostat or placebo. During the 12-week&#xD;
      double-blind, placebo-controlled Treatment period, patients will return for assessments in&#xD;
      accordance with the schedule of assessments. At the conclusion of the approximately 12 week&#xD;
      open label Safety Extension period, patients will enter a Follow-up safety washout and&#xD;
      assessment period, which will incorporate 2 visits at approximately 2 and 4 weeks following&#xD;
      the final Safety Extension visit, with assessments performed as outlined in the schedule of&#xD;
      assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Average Pain Intensity (NRS)</measure>
    <time_frame>Baseline week [Day-7 to Day 1] compared to Final week [12 Weeks]</time_frame>
    <description>Difference between mean average pain intensity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Average Pain Intensity (NRS)</measure>
    <time_frame>Baseline week [Day-7 to Day 1] compared to Week 4</time_frame>
    <description>Difference between mean average pain intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-pain Neuropathic Signs (UENS)</measure>
    <time_frame>Baseline week [Day-7 to Day 1] compared to Week 12</time_frame>
    <description>Change in non-pain neuropathic signs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">274</enrollment>
  <condition>Painful Diabetic Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>ricolinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ricolinostat 120 mg, taken once daily (QD) by mouth; each dose in 12 mL liquid formulation (10 mg ricolinostat per mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 12 mL of liquid formulation with no active ingredient (i.e., ricolinostat), taken once daily (QD) by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ricolinostat</intervention_name>
    <description>120 mg per dose in 12 mL liquid formulation</description>
    <arm_group_label>ricolinostat</arm_group_label>
    <other_name>ACY-1215</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>12 mL liquid formulation placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 or Type 2 diabetes of at least 6 months with optimized and stable glycemic&#xD;
             control during the 3 months prior to Screening&#xD;
&#xD;
          -  Painful distal symmetric sensorimotor polyneuropathy due to diabetes&#xD;
&#xD;
          -  Douleur Neuropathique 4 (DN4) score of ≥4&#xD;
&#xD;
          -  Satisfactory diary data during the 14-day Pain Observation period determined by an&#xD;
             algorithm that includes diary compliance, overall level of pain and day-to-day&#xD;
             variability in pain&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt;40 kg/m2&#xD;
&#xD;
          -  Presence of any neuropathy other than DPN and/or significant risk factors for&#xD;
             neuropathy other than diabetes&#xD;
&#xD;
          -  Other pain conditions that could confound the results of this study, or other chronic&#xD;
             pain condition(s) that could affect compliance with pain medication restrictions or&#xD;
             confound pain assessments&#xD;
&#xD;
          -  Painful DPN patients who have undergone lower limb amputations, are non-ambulatory, or&#xD;
             whose walking is so impaired as to require a walker or other assistance for ambulation&#xD;
&#xD;
          -  Have met Diagnostic and Statistical Manual of Mental Disorders V (DSM V) criteria for&#xD;
             opioid use disorder or alcohol use disorder&#xD;
&#xD;
          -  Opioid use at a dose of ≥ 30 morphine milligram equivalents on 3 or more days a week&#xD;
             during the month prior to Screening&#xD;
&#xD;
          -  Suicidal ideation/behavior as measured by the Columbia-Suicide Severity Rating Scale&#xD;
             (C-SSRS)&#xD;
&#xD;
          -  The use of marijuana or cannabidiol (CBD) during the 30 days prior to starting study&#xD;
             drug&#xD;
&#xD;
          -  Chronic use of over-the-counter capsaicin on extremities within 3 months of Screening&#xD;
             and/or prescription Qutenza use within 6 months of Screening&#xD;
&#xD;
          -  Corrected QT interval at Screening using QTcF of ≥450 msec (male) or ≥460 msec&#xD;
             (female)&#xD;
&#xD;
          -  Hemoglobin &lt; 11.5 g/dL (female) or &lt; 13 g/dL (male), total white blood cell count &lt;&#xD;
             2500/mm3, neutrophil count &lt; 1250/mm3, lymphocyte count &lt; 1000/mm3, or platelet count&#xD;
             &lt; 100,000/mm3&#xD;
&#xD;
          -  HIV positive and/or active hepatitis virus (A, B, or C) infection&#xD;
&#xD;
          -  Current or previous (≤1 month of Screening) enrollment in a clinical trial involving&#xD;
             treatment with an investigational product&#xD;
&#xD;
          -  Any known recent exposure within the 14 days prior to initial Screening to coronavirus&#xD;
             disease 2019 (COVID-19) or symptoms of COVID-19 infection or other reason to suspect&#xD;
             COVID-19 infection as assessed by the Investigator at the time of initial Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Michelson, MD</last_name>
    <phone>617-415-5030</phone>
    <email>dmichelson@regenacy.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pinnacle Research Group LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Almena L Free, MD/CCRP</last_name>
      <phone>256-236-0055</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph S Gimbel, MD</last_name>
      <phone>602-863-6363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diabetes/Lipid Management &amp; Research Center</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul D Rosenblit, MD, PhD</last_name>
      <phone>714-375-7386</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanley Hsia, MD</last_name>
      <phone>323-588-1968</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Altman Clinical and Translational Research Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Wallace, MD</last_name>
      <phone>858-822-0776</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Torrance Clinical Research Institute Inc</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Raikhel, MD</last_name>
      <phone>310-373-8120</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Clinical Research</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa S Sligh, MD, CPI</last_name>
      <phone>818-558-7555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research Inc</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Reyzelman, DPM</last_name>
      <phone>800-363-1069</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research Inc</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark P Christiansen, MD</last_name>
      <phone>925-930-7267</phone>
      <phone_ext>226</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida Inc</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel E Trevino, MD</last_name>
      <phone>727-584-6368</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>DeLand Clinical Research Unit</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce G Rankin, DO, FACOFP</last_name>
      <phone>386-740-0770</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ClinCloud LLC</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malisa Agard, MD</last_name>
      <phone>407-636-4031</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>APF Research LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon F Sastre, MD</last_name>
      <phone>786-220-9450</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>International Research Associates LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33183</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian F Breton, MD</last_name>
      <phone>305-670-8830</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sensible Healthcare LLC</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Taylor, MD</last_name>
      <phone>407-654-2724</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Billmeier, MD</last_name>
      <phone>386-304-7070</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah A Burke, MD, M.Ed.</last_name>
      <phone>813-877-8839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Metabolic Research Institute Inc</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry S Horowitz, MD</last_name>
      <phone>561-802-3060</phone>
      <phone_ext>8027</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Physicians Research Associates, LLC</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adeniyi O Odugbesan, MD MRCP FACE</last_name>
      <phone>678-252-2375</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Clinical Research</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl D Vance, MD</last_name>
      <phone>208-522-6005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MediSphere Medical Research Center, LLC</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert S Reyes, MD</last_name>
      <phone>812-471-4110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tandem Clinical Research</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Reiss, MD, MBA</last_name>
      <phone>504-934-8424</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Olive Branch Family Medical Center</name>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <zip>38654</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randall T Huling Jr, MD, CPI</last_name>
      <phone>662-893-8474</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Biomedical Research of America</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yekaterina A Khronusova, MD</last_name>
      <phone>702-898-2088</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael A Hassman, DO</last_name>
      <phone>856-753-7335</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NY Scientific</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Brun, MD</last_name>
      <phone>347-986-3749</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Triad Clinical Trials</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard I Montgomery, MD</last_name>
      <phone>336-235-0991</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard L Rauck, MD</last_name>
      <phone>336-765-6181</phone>
      <phone_ext>146</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rica Santiago, MD</last_name>
      <phone>843-856-3784</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Research</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Bolster, MD</last_name>
      <phone>843-851-7098</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Neurology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John D Hudson, MD</last_name>
      <phone>512-380-9925</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nerve and Muscle Center of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aziz Shaibani, MD</last_name>
      <phone>713-795-0033</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Research Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl E Dukes, MD,FACP</last_name>
      <phone>210-227-1289</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Glandular Disease Clinic, P.A.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Kipnes, MD</last_name>
      <phone>210-615-5565</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wasatch Clinical Research LLC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D Killpack, MD</last_name>
      <phone>801-288-0607</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Neuropathic Pain</keyword>
  <keyword>Neuropathic Pain</keyword>
  <keyword>HDAC6</keyword>
  <keyword>ricolinostat</keyword>
  <keyword>Painful Diabetic Peripheral Neuropathy</keyword>
  <keyword>DPN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ricolinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

